Site brasileiro onde você pode comprar qualidade e entrega viagra preço cialis barato em todo o mundo.

Curriculum vitae

CURRICULUM VITAE
Revised: May 2011
BAXTER DELWORTH MONTGOMERY, MD

PRESENT TITLES:

Clinical Assistant Professor
The University of Texas Health Science Center
Department of Medicine
Division of Cardiology/Clinical Cardiac
Electrophysiology

President and CEO
Houston Associates of Cardiovascular Medicine,
PA. (1997- Present)

Executive Director
The Johnsie and Aubary Montgomery Institute
of Medical Education and Research (a 501 (c) 3
nonprofit organization)


BIRTHDATE:

February 21, 1964

BIRTH PLACE:

Houston, Texas
United States of America

OFFICE ADDRESS:

10480 South Main St.
Houston, Texas 77025
(713) 599-1144 phone
(713) 599-1199 fax
bmontgomery@drbaxtermontgomery.com

UNDERGRADUATE
EDUCATION:

William Marsh Rice University
Houston, Texas
Bachelor’s Degree in Biochemistry (1986)

GRADUATE
EDUCATION:
The University of Texas Medical Branch at
Galveston

Galveston, Texas
Doctor of Medicine

RESIDENCY:

Baylor College of Medicine
Houston, Texas
Internal Medicine
FELLOWSHIP:
The University of Texas Health Science Center
at Houston

Houston, Texas
Cardiovascular Diseases
Clinical Cardiac Electrophysiology

CERTIFICATION:
Diplomate of the American Board of Internal
Medicine, Cardiovascular Diseases


Diplomate of the American Board of Internal
Medicine, Clinical Cardiac Electrophysiology


LICENSURE:

Texas State Board of Medical Examiners (Since
Permit Number H9549

HOSPITAL APPOINTMENTS:

Attending Physician
Memorial Hermann Hospital – The Texas
Medical Center

Houston, Texas
Attending Physician
The Heart and Vascular Institute

Memorial Hermann Hospital – The Texas
Medical Center

Houston, Texas
Consulting Physician
Select Specialty Hospital – Heights
Houston, Texas

TEACHING
RESPONSIBILITIES:

Teaching Faculty for Cardiology Fellows and
Clinical Advanced Nurse Practitioners
The Heart and Vascular Institute
Memorial Hermann Hospital – Texas Medical
Center
1997 – Present


Cardiovascular Disease Lecturer
GlaxoSmithKline, Inc.
2000 – Present
Cardiovascular Disease Lecturer
Novartis, Inc.
2006 – Present
Cardiovascular Disease Lecturer
Boston Scientific, Inc.
2006 – Present
Co-Director and Lecturing Faculty
Cardiology Concepts for Non-Cardiologists
(An Annual Houston Area Educational
Symposium)
JAM Institute, Inc.
2006 – 2008
Steering Committee Member and Lecturing
Faculty
Close the Gap

Boston Scientific, Inc.
2006 – Present

RESEARCH:
CLINICAL STUDIES:
ALLHAT: Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack
Trial.
ALLHAT was a blinded, randomized trial
that investigated the relative efficacy of different
classes of antihypertensive agents in reducing
stroke, illness and death from cardiovascular
diseases. A subgroup of patients with
hyperlipidemia was randomized comparing
Pravastatin compared to usual care.
A Houston Site – Principal Investigator (1998)
INVEST: The International Verapamil SR/
Trandolapril Study.
INVEST was a randomized
controlled clinical trial comparing a calcium
antagonist treatment strategy (Isoptin® SR) with a
non calcium antagonist treatment strategy for the
control of hypertension in a primary care coronary
artery disease patient population.
A Houston Site – Principal Investigator (1998)
INVEST SUB-STUDY:
This study was a sub-
study of the INVEST patient population designed to
evaluate the impact of genetic differences on
pharmacokinetics.
A Houston Site – Principal Investigator (2000)
The Safety and Efficacy of PNU-182716 Versus
Rosiglitazone:
This was a one-year, randomized,
double blind, parallel group, and active comparator
study.
A Houston Site – Principal Investigator (2000)
FACTOR: Fenofibrate and Cerivastatin Trial
Optimizing Response.
FACTOR was a
multicenter, randomized, double blind, placebo
controlled, parallel group, study of the safety and
efficacy of Cerivastatin in combination with
Fenofibrate compared to Cerivastatin alone,
Fenofibrate alone and placebo in a population of
Type 2 Diabetic Men and Women.
Grant Sponsor – Bayer 2001
A Houston Site – Principal Investigator
ADHERE: ADHERE was a national registry of
patients admitted to hospitals with acute
decompensated congestive heart failure.
A Houston Site – Principal Investigator (2001)

STELID TM AND STELIX TM LEADS
STUDY:
This study was a safety and efficacy
study of steroid-eluting cardiac pacing leads.
Grant Sponsor – Ella Medical 2002
A Houston Site – Principal Investigator
ARRHYTHMIA PATHWAY STUDY:
This was
a patient registry study designed to assess the
efficacy of a clinical algorithm for identifying and
assessing patients at risk of sudden cardiac arrest.
Grant Sponsor – Medtronic, Inc. 2002
A Houston Site – Principal Investigator


RAPIDO CATHETER STUDY:
This study was
designed to evaluate the efficacy of a left
ventricular defibrillator-pacemaker lead delivery
system.
Grant Sponsor – Guidant, Inc. 2003
A Houston Site – Principal Investigator

PROTOS HEART RATE DISTRIBUTION
STUDY:
This was a clinical study designed to
compare the heart rate distribution in patients
undergoing pacemaker implants requiring heart rate
response therapy. This study compared the heart
rate distribution of accelerometer rate response
therapy to the BIOTRONIK Closed Loop System
therapy.
Grant Sponsor – Biotronik, Inc. 2003
A Houston Site – Principal Investigator
CSPP100A2404- A 54 week, randomized, double-
blind, parallel-group, multicenter study evaluating
the long-term gastrointestinal (GI) safety and
tolerability of Aliskiren (300 mg) compared to
Ramipril (10 mg) in patients with essential
hypertension.
Sponsored by Novartis, since April 4, 2008.
CSPP100AUS03-
Multicenter, Randomized, Double-Blind, Active
Control, Parallel Group Study to Evaluate the
Efficacy and Safety of Aliskiren HCTZ versus
Amlodipine in African American Patients with
Stage 2 Hypertension.
Sponsored by Novartis, since August 2008.
CSPP100A2409- An 8 week randomized, double-
blind, parallel-group, multicenter, active-controlled
dose escalation study to evaluate the efficacy and
safety of Aliskiren HCTZ (300/25 MG) compared
to Amlodipine (10 mg) in patients with satage 2
systolic hypertension and diabetes mellitus.
Sponsored by Novartis, since December 2008.
SPA100AUS01-
Randomized, Double-blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren Administered in Combination with
Amlodipine (150/5mg, 300/10 mg) versus
Amlodipine alone (5 mg, 10 mg) in African
American patients with stage 2 hypertension.
Sponsored by Novartis, since February 2009.
CLAF237B2201- A multicenter, randomized,
double-blind study to evaluate the efficacy and
long-term safety of vildagliptin modifies release
(MR) as monotherapy in patients with type 2
diabetes.
Sponsored by Novartis, since February 2009.
CLAF237B2224- A multi-center, randomized,
double-blind study to evaluate the efficacy and
long-term safety of vildagliptin modified release
(MR) as add-on therapy to metformin in patients
with type 2 diabetes.
Sponsored by Novartis, since February 2009.
BASIC RESEARCH:
Increased Frequency of the Deletion Allele of the
ACE Gene in African-Americans Compared to
Caucasians
. This study evaluated the prevalence of
the deletion allele of the ACE gene in a population
of African Americans compared to Caucasians. The
findings were presented at the annual meeting of the
American College of Cardiology in March of 1996.
Determination of the effect of Calcium infusion
on CGRP mRNA Production.
A pilot study
investigating a possible mechanism by which
calcium supplementation may increase CGRP
(Calcitonin gene-related peptide, a potent peripheral
vasodilator) content in afferent neurons of Sprague
Dawley rats, 1990.
The Adenine Nucleotide Pool-Size of Heart
Mitochondria is Regulated by the ADP/ATP
Translocase.
Abstract presented at the 29th Annual
National Student Research Forum, University of
Texas Medical Branch, Galveston Texas, April 6-8,
1988.
Regulation of the Adenine Nucleotide Pool-Size
of Heart Mitochondria by the ADP/ATP
Translocase.
Abstract and poster presented at the
Galveston-Houston Conference for Cardiovascular
Research, Univ. of Texas, Medical Branch,
Galveston, TX, February 26, 1988.
Rapid Separation of Mitochondria from Extra-
mitochondrial Space Applied to Rat Heart
Mitochondria.
An abstract presented at an NIH
sponsored student research poster session, Univ. of
Texas Medical Branch, Galveston, TX, June 17,
1987.

PUBLICATIONS:

Montgomery, Baxter D: The Food Prescription for
Better Health, Houston: Delworth Publishing, 2011
Doyle, N.M., Monga, M., Montgomery, B.,
Dougherty, A.H.: Arrhythmogenic right ventricular
cardiomyopathy with implantable cardioverter
defibrillator placement in pregnancy. J Mat Fetal
Neo Med 18:141-4, 2005
Baxter D. Montgomery, MD, Elizabeth A.
Putnam, Ph.D., John Reveille, MD, Dianna M.
Milewicz. MD, Ph.D.: Increased Frequency of the
Deletion Allele of the ACE Gene in African-
Americans Compared to Caucasians. (Abstract) J.
American College of Cardiology March, 1996
Montgomery, B, D., A Review of Microanatony
for Medical Students, 1987, chapter 1-8.

CLINICAL
PRESENTATIONS:

Clinical Concepts for Non Cardiologists, Director and Faculty. An educational symposium held for primary care and other non-cardiology specialists in the Houston area. October, 2006. Clinical Concepts for Non Cardiologists, Co-Director and Faculty. An educational symposium held for primary care and other non-cardiology specialists in the Houston area. October, 2007. Patients at Risk for Sudden Cardiac Arrest Dinner Symposium at the Houston Forum June, 2007 January, 2006

PROFESSIONAL APPOINTMENTS:

Clinical Assistant Professor of Medicine, University of Texas Health Science Center – Houston 1996 – Present Steering Committee Member, Boston Scientific Close the Gap Initiative 2005 – Present Scientific/Medical Board of Advisors, Nutritional Excellence, Inc. 2007 – Present Medical Board of Directors, Twelve Oaks Medical Center Independent Physician’s Association 2005 – Present Medical Executive Committee (Twelve Oaks Hospital), Member at Large 2002 – 2006 Patient Safety Committee (Twelve Oaks Hospital), Chairman 2002 – 2004 Physician Peer Review Committee (Twelve Oaks Hospital) 2002 – 2005 Medical Director, SCCI (Specialized Complex Care) Hospital, 2003 – 2005 Physician Relation Council Advisory Board, Unicare, 2002 – 2004 CLINICAL INTERESTS:
Cardiac Pacing and Electrophysiology Sudden Cardiac Arrest Diastolic and Systolic Heart Failure Hypertensive Heart Disease Cardiovascular Exercise Physiology
PROFESSIONAL ASSOCIATIONS:
American College of Cardiology (Elected as Fellow Heart Rhythm Society (North American Society of
HONORS AND AWARDS

Cumulative evaluation of “Superior” performance by senior house staff and faculty during first year of residency (Baylor College of Medicine), 1990 Kempner Award (University of TX Medical Academic Scholarship (University of TX Medical Franz Brotzen Outstanding Senior Award (Rice Jones College Service Award (Rice University) ACTIVITIES:

Source: http://www.whatcanieatfoundation.org/wp-content/uploads/DrBaxterMontgomeryCV.pdf

Délibération de la cre du 11 décembre 2013 portant décision d’approbation du programme d’investissements de rte pour 2014

Délibération Délibération de la Commission de régulation de l’énergie du 11 décembre 2013 portant décision d’approbation du programme d’investissements de RTE pour 2014 Participaient à la séance : Olivier CHALLAN BELVAL, Hélène GASSIN et Jean-Pierre SOTURA, commissaires En application des dispositions du 2° de l’article L. 134-3 du code de l’énergie, le gestionnai

Biomist4+4_al0084_sample

BIOMIST® 4+4 ULV www.clarkemosquito.com For Use Outdoors as an Ultra-Low Volume (ULV) Application to Control Adult Mosquitoes in Residential andRecreational Areas. This product is highly toxic to bees exposed to direct treatment on blooming crops orPermethrin (3-Phenoxyphenyl) methyl (+/-) cis,weeds. Do not apply this product or allow it to drift to blooming crops or weeds whiletrans-3-

Copyright © 2010-2014 Articles Finder